Aurobindo Pharma today said it has received approval from the Canadian health regulator to sell its anti-infective drug in the country.
The company has received approval for its abbreviated new drug submission, 'Cefotaxime Sodium' injections, from Health Canada, Aurobindo Pharma said in a statement.
The company has been given approval to market the drug in strengths of 0.5 mg, 1 gram and 2 grams.
With this approval, the company now has 13 product approvals from Health Canada.
The drug, which is the generic equivalent of the Claforan tablets of Sanofi-Aventis, falls under the anti-infective therapeutic segment and is used for treatment of various infections, including pneumonia and urinary tract infections.
Shares of Aurobindo Pharma were today trading at Rs 842 on the BSE, down 1.47 per cent from the previous close.